Exact Sciences Corp (NAS:EXAS)
$ 49.84 -4.24 (-7.84%) Market Cap: 9.20 Bil Enterprise Value: 11.10 Bil PE Ratio: 0 PB Ratio: 2.93 GF Score: 80/100

Exact Sciences Corp at Canaccord Genuity Growth Conference Transcript

Aug 07, 2019 / 01:00PM GMT
Release Date Price: $114.53 (+1.39%)
Mark Anthony Massaro
Canaccord Genuity Corp., Research Division - Senior Analyst

We're going to get started. It's 9:00. Very pleased to welcome back Exact Sciences. Many of you know Exact and have seen their commercials. They sell Cologuard. It's a tremendous noninvasive colon cancer screening test. The company has really been a spectacular stock. They've been one of our top picks for the last 3 consecutive years. The returns have been outstanding. Exact remains a top pick, and they just came off a very strong Q2. They also came off a surprising announcing to acquire Genomic Health, which was just last week. So I'm really pleased to welcome back Exact's CFO, Jeff Elliott.

Thanks, Jeff, for being here.

Jeffrey T. Elliott
Exact Sciences Corporation - CFO

Thanks, Mark. It's good to be back.

Questions & Answers

Mark Anthony Massaro
Canaccord Genuity Corp., Research Division - Senior Analyst

All right. So why don't we start with the Genomic Health acquisition? You named a long list of reasons to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot